Lipid

Fatostatin is a specific inhibitor of SREBP activation, it impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs.

1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium (1,2-Dioleoyl-sn-glycero-3-PS (sodium salt)) can be used in lipid mixtures with DOPC and DOPE as effective nontoxic and nonviral DNA vectors. It has been utilized in the formation of unilamellar vesicles to study membrane structure curvature and in supported lipid bilayers to examine the impact of various support materials on lipid redistribution between membrane leaflets.

Betulin (betulinol) (lup-20(29)-ene-3β, 28-diol) is an abundant, naturally occurring triterpene. It is commonly isolated from the bark of birch trees where it forms up to 30% of the dry weight of the extractive and is found in birch sap as well.

Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials.

Fenipentol (Pancoral) has the properties of Choleretics and Cholagogues.

PF-429242 is a competitive inhibitor of sterol regulatory element-binding protein (SREBP) site 1 protease (IC50 = 0.175 μM). It is selective for site 1 protease against a panel of serine proteases. PF-429242 inhibits rate of cholesterol synthesis in CHO c

HSL-IN-1 is an orally active and highly potent hormone-sensitive lipase (HSL) inhibitor that significantly reduces the reactive metabolite load and can reduce the release of free fatty acids from stored fat.

Atractylodin (Atractydin) has high lipase inhibitory activity (IC5:39.12 μM); Atractylodin possesses strong repellency activities against T. castaneum adults (LD50: 1.83 μg cm). The repellency of Atractylodin (0.63 μg cm) can achieve >90%.

Dehydrocholate sodium, a hydrocholeretic, can increase bile output to clear increased bile acid load.

MAGL-IN-5 is a non-selective lipase inhibitor.

Lifibrol (U-83860) is an inhibitor of cholesterol synthesis.Lifibrol has anticholesterol and hypolipidemic properties and promotes the conversion of LDL Apo B-100 in patients with hypercholesterolemia and mixed hyperlipidemia.

Carboxylesterase-IN-3 is a potent inhibitor of Carboxylesterase Notum (IC50 ≤ 10 nM).Carboxylesterase-IN-3 has the potential to study cancer diseases.

MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist. It potently inhibits the expression of iNOS, low SREBP-induced and activated RXR, and p-ERK at the protein level. MSU-42011 has demonstrated antitumor activity in a [kras]-driven mouse model of lung cancer and is effective for the treatment of preclinical [kras]-driven lung cancer with immunomodulatory activity.

Ethyl phenylglyoxylate (AI3 10033) is a simultaneous inhibitor and substrate of chicken liver carboxylesterase.

VK-28 is a brain permeable iron chelator with neuroprotection. VK-28 inhibits basal as well as iron-induced mitochondrial lipid peroxidation.

Cetilistat (ATL-962) is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

Carboxylesterase-IN-2 is a potent Carboxylesterase Notum inhibitor (IC50 <= 10 nM).Carboxylesterase-IN-2 has potential for the study of cancer diseases.

Isolicoflavonol is a potential cancer chemopreventive agent.

Icariside E4 is a natural compound derived from Ulmus minor that acts via AMPK phosphorylation and inhibition of MID1IP2 hypolipidation in HepG1 cells.Icariside E4 has anti-injurious, antioxidant, anti-Alzheimer's and anti-inflammatory effects and inhibits SREBP-1c, liver X receptor-α (LXR) and FASN in Icariside E4 is an effective candidate for the treatment of fatty liver disease and has hypolipidemic potential in HepG1 cells.